Why Infinity Pharmaceuticals (INFI) Stock Is Getting Obliterated
Why Infinity Pharmaceuticals (INFI) Stock Is Getting Obliterated
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) shares are trading lower by 40.3% to $0.13 Monday morning after it terminated its previously announced merger agreement with MEI Pharma.
英菲尼迪製藥公司 納斯達克股票代碼：INFI）週一上午股價下跌40.3％，至0.13美元，此前該公司終止了先前宣佈的與之的合併協議 MEI 製藥。
What Happened?
發生了什麼？
Infinity Pharmaceuticals terminated its merger agreement with MEI Pharma after MEI failed to obtain stockholder approval for the merger. Infinity's board of directors will explore strategic alternatives for its eganelisib drug, including engaging strategic advisors for potential value realization.
在MEI未能獲得股東批准合併後，Infinity Pharmicals終止了與MEI Pharma的合併協議。Infinity的董事會將探索其eganelisib藥物的戰略替代方案，包括聘請戰略顧問來實現潛在的價值。
MEI may be required to reimburse Infinity for certain expenses and fees of $1 million in accordance with the terms of the merger agreement.
根據合併協議的條款，MEI可能需要向Infinity償還100萬美元的某些費用和費用。
An additional $4 million termination fee from MEI remains a possibility under specified circumstances outlined in the joint proxy statement/prospectus relating to the merger.
在與合併有關的聯合委託書/招股說明書中概述的特定情況下，MEI仍有可能額外收取400萬美元的解僱費。
See Also: First Citizens Bank Provides A $1M Line Of Credit To The Georgia Hemp Company
另見：第一公民銀行向佐治亞州大麻公司提供100萬美元的信貸額度
According to data from Benzinga Pro, INFI has a 52-week high of $1.76 and a 52-week low of $0.12.
根據Benzinga Pro的數據，INFI創下52周高點爲1.76美元，52周低點爲0.12美元。